The global cell therapy market size was valued at USD 5.6 Bn in 2022 and is expected to reach USD 17.52 Bn by 2031, expanding at a CAGR of 17.8% during 2023 – 2031. Increasing adoption of regenerative medicine for treatments due to the rising prevalence of chronic disorders among the aged population is anticipated to boost the market.
Cell therapy also known as cellular therapy is an innovative medical approach that involves the transplantation or manipulation of human cells to repair or replace damaged tissues or to treat various diseases and conditions. It utilizes living cells either from the patient's own body (autologous) or from a donor (allogeneic) to restore or enhance the function of damaged or diseased tissues. This innovative technique helps in treating a wide range of ailments.
Cell therapy offers personalized therapy by using a patient's own cells, which reduces the risk of rejection and eliminates the need for immunosuppressive drugs. This therapy has the potential to repair and regenerate damaged tissues and organs, which provides long-lasting and often permanent solutions to patients. Moreover, cell therapy has the ability to target the root cause of a disease rather than merely managing symptoms leading to improved outcomes and quality of life of patients.
Cell therapy is utilized in various medical fields. In oncology, it has been used to harness the immune system to fight cancer cells, leading to the development of immunotherapies such as CAR-T cell therapy. In this approach, T cells from a patient's own immune system are genetically modified to express chimeric antigen receptors (CARs) that specifically recognize and destroy cancer cells.
The remarkable success of CAR-T cell therapy in treating certain types of leukemia and lymphoma has demonstrated its immense potential in the fight against cancer.
The COVID-19 pandemic moderately impacted the cell therapy market. The restrictions imposed by the government to curb the spread of the virus, such as lockdowns, travel limitations, and social distancing measures had disrupted clinical trials and research activities. Many ongoing trials had to be put on hold, which affected cell therapy development. However, the pandemic created potential opportunities for cell therapy in addressing infectious diseases and developing novel treatments.
The urgent need for effective therapies and vaccines against the virus accelerated research in cell-based approaches. Mesenchymal stem cells, a type of stem cell with immunomodulatory properties gained a significant increase in reducing the severity of COVID-19-related complications and in promoting tissue repair.
-
For instance, on August 3, 2020, Calidi Biotherapeutics, a global biotechnology company, announced that its partner, Personalized Stem Cells, Inc., has received FDA approval to treat COVID-19 patients through stem cell therapy.
Cell Therapy Market Dynamics
Major Drivers
Increasing prevalence of chronic diseases and rising demand for innovative treatment options are expected to drive the market during the projected period. Conditions such as cancer, cardiovascular disorders, neurodegenerative diseases, and autoimmune disorders pose significant challenges in the healthcare sector worldwide.
Cell therapy offers innovative and potentially curative treatment approaches by targeting the underlying causes of these diseases. The growing need for effective and long-lasting therapies is further likely to boost the demand for cell-based treatments.
-
For instance, according to a report published by the Ministry of Science and Technology on February 10, 2023, globally chronic or non-communicable diseases are on the rise and are the primary reason for 73% of all deaths. Whereas, in India, non-communicable diseases accounted for 53% of all deaths.
Existing Restraints
High cost associated with cell therapies is expected to hinder the market. The development, manufacturing, and delivery processes for cell therapy equipment are complex and resource-intensive. The need for specialized facilities, skilled personnel, and stringent quality control measures contribute to the high costs involved in producing and delivering cell-based treatments.
The high cost of cell therapies poses challenges in terms of accessibility, reimbursement, and affordability, which limit their availability to a wider patient population.
Emerging Opportunities
Increasing research activities and advancements in technology are likely to create favorable opportunities for the key players competing in the market. Researchers are exploring the use of cell therapies in treating neurodegenerative diseases, cardiovascular disorders, autoimmune conditions, and genetic disorders.
These expanded applications offer the prospect of addressing significant unmet medical needs and improving outcomes for patients in various therapeutic areas. Furthermore, the convergence of cell therapy with other fields such as gene editing, regenerative medicine, and biomaterials opens up new avenues for innovation and therapeutic possibilities.
Scope of the Cell Therapy Market Report
The report on the market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Cell Therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Cell Type (Stem and Non-stem), Therapy Type (Autologous and Allogeneic), Application (Oncology, Cardiovascular Diseases, Orthopedics, Wound Healing, Malignancies, Musculoskeletal Disorder, Autoimmune Disorder, Dermatology, and Others), and End-user (Hospitals & Clinics, Research Institutes, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Allosource; Atara Biotherapeutics, Inc.; Bluebird Bio, Inc.; Bristol-Myers Squibb Company; Castle Creek Biosciences, Inc; CORESTEM, Inc; CHIESI Farmaceutici S.p.A.; Cells for Cells S.A.; Dendreon Pharmaceuticals LLC.; Gilead Sciences, Inc.; JCR Pharmaceuticals Co., Ltd.; Johnson & Johnson Services, Inc; Kolon TissueGene, Inc.; The Future of Biotechnology; Novartis AG; NuVasive®, Inc.; Pharmicell Co.,Ltd.; Stemedica Cell Technologies, Inc.; Takeda Pharmaceutical Company Limited.; and Tegoscience
|
Cell Therapy Market Segment Insights
Cell Type Segment Analysis
Based on cell type, the cell therapy market is bifurcated into stem and non-stem. The stem segment is expected to grow at a significant CAGR in the coming years, owing to its wide range of potential applications in cell therapy. Stem cells have the ability to self-renew and differentiate various specialized cell types, which makes them valuable tools in regenerative medicine.
Stem cell therapies play a vital role in treating a diverse array of diseases and conditions, including neurodegenerative disorders, cardiovascular diseases, orthopedic injuries, and autoimmune disorders. This type of cell replaces cells damaged by chemotherapy or other diseases.
The versatility and therapeutic potential of stem cells make them a preferable choice in the field of cell therapy. Moreover, stem cells are easily derived from various sources, including embryonic stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs). This diversity of cell sources enhanced flexibility in the selection of appropriate stem cell types based on specific therapeutic needs.
Therapy Type Segment Analysis
On the basis of therapy type, the market is divided into autologous and allogeneic. The autologous segment is expected to hold a major market share during the forecast period, due to its various advantages such as the reduced risk of immune rejection and relatively easier access to patient-derived cells. Autologous therapies align closely with the principles of personalized medicine by tailoring treatments to the specific needs of each patient.
The ability to customize cell therapies based on an individual's unique characteristics and medical history allows for a more targeted and potentially effective treatment approach. These factors contribute to the preference for autologous therapies in certain disease areas.
The availability of patient-derived cells is relatively easier and more convenient in autologous therapies compared to allogeneic therapies. The patient's own cells for therapy are often done through minimally invasive procedures such as peripheral blood collection or tissue biopsy. Moreover, ease of access to the required cells simplifies the logistics and reduces the need for donor matching and complex immunosuppressive regimens.
The allogeneic segment is expected to expand at a considerable CAGR during the projection period, owing to its superior advantages over autologous therapies, where a patient's own cells are used. Allogenic therapies involve the use of cells obtained from healthy donors, which allows for the creation of different products that are readily available for patients.
This eliminates the need for complex and time-consuming processes of harvesting and expanding a patient's own cells, which makes it more accessible and cost-effective. The convenience and scalability of allogenic therapies further contribute to segment growth.
Application Segment Analysis
Based on application, the cell therapy market is classified as oncology, cardiovascular diseases, orthopedics, wound healing, malignancies, musculoskeletal disorder, autoimmune disorder, dermatology, and others. The oncology segment is anticipated to register a robust growth rate in the coming years, owing to the remarkable success of cell therapies in treating certain types of cancer.
Chimeric antigen receptor T-cell therapy (CAR-T) has witnessed growth in the management of hematological malignancies, such as leukemia and lymphoma. CAR-T therapy involves modifying a patient's own immune cells to specifically target areas and eliminate cancer cells. The significant advancements and positive clinical outcomes in CAR-T therapy have propelled its adoption and contributed to the dominance of the oncology segment within the cell therapy market.
The malignancies segment is anticipated to grow at a significant pace during the assessment period, owing to the rising adoption of cell therapies to treat malignancies. The increasing incidence of cancer globally coupled with the limitations of conventional therapies has created a substantial need for innovative and effective treatment options. Cell therapy helps to harness the power of the immune system and target cancer cells, which holds tremendous promise in revolutionizing the management of malignancies.
Ongoing research and development in cell therapies for malignancies contribute to the expansion of this segment in the market. Furthermore, researchers and biopharmaceutical companies are continuously developing innovative cell therapy approaches and conducting clinical trials to evaluate their efficacy in various types of cancer.
End-user Analysis
In terms of end-user, the market is fragmented into hospitals & clinics, research institutes, and others. The hospitals & clinics segment is estimated to hold a key market share during the projected period, due to their existing infrastructure, expertise in administering advanced treatments, and the ability to provide comprehensive care and support.
Hospitals are equipped with specialized departments and personnel experienced in handling and administering cell-based treatments. Hospitals and specialized clinics allow for the seamless integration of cell therapies into existing healthcare systems, facilitating the adoption and utilization of these advanced therapies.
The research institutes segment is anticipated to grow at a significant growth rate in the coming years, owing to their pivotal role in advancing scientific knowledge, securing funding, and providing training and education. These institutes are at the forefront of cell therapy research and development.
These institutions have dedicated teams of scientists, researchers, and clinicians who focus on studying the biology of cells, developing new therapeutic approaches, and conducting preclinical trials. Research institutes possess the necessary expertise to explore the potential of cell therapies across various therapeutic areas.
Regional Outlook
In terms of region, the global cell therapy market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period, due to the wide presence of well-established healthcare infrastructure and research institutes working in stem cell treatments.
The region has world-class hospitals, clinics, and research institutions that are at the forefront of medical advancements. These institutions have the expertise, resources, and capabilities to conduct clinical trials, develop innovative cell therapies, and provide specialized care to patients.
Asia Pacific is anticipated to expand at a rapid pace in the global market in the coming years, owing to the rising demand for cell therapies for treating cancer and managing chronic diseases. This region is home to a thriving biopharmaceutical industry, where several key players are actively engaged in cell therapy research and development.
Local companies and research institutions are collaborating with international partners, conducting clinical trials, and advancing the field of cell therapy. However, rising government initiatives to improve healthcare infrastructure is likely to fuel the market in the region.
Segments
The global cell therapy market has been segmented on the basis of
Cell Type
Therapy Type
Application
- Oncology
- Cardiovascular Diseases
- Orthopedics
- Wound Healing
- Malignancies
- Musculoskeletal Disorder
- Autoimmune Disorder
- Dermatology
- Others
End-user
- Hospitals
- Specialty Clinics
- Research Institutes
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Allosource
- Atara Biotherapeutics, Inc.
- Bluebird Bio, Inc.
- Bristol-Myers Squibb Company
- Castle Creek Biosciences, Inc
- CORESTEM, Inc
- CHIESI Farmaceutici S.p.A.
- Cells for Cells S.A.
- Dendreon Pharmaceuticals LLC.
- Gilead Sciences, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Johnson & Johnson Services, Inc
- Kolon TissueGene, Inc.
- The Future of Biotechnology
- Novartis AG
- NuVasive®, Inc.
- Pharmicell Co.,Ltd.
- Stemedica Cell Technologies, Inc.
- Takeda Pharmaceutical Company Limited.
- Tegoscience
Competitive Landscape
Key players competing in the global cell therapy market are Allosource; Atara Biotherapeutics, Inc.; Bluebird Bio, Inc.; Bristol-Myers Squibb Company; Castle Creek Biosciences, Inc; CORESTEM, Inc; CHIESI Farmaceutici S.p.A.; Cells for Cells S.A.; Dendreon Pharmaceuticals LLC.; Gilead Sciences, Inc.; JCR Pharmaceuticals Co., Ltd.; Johnson & Johnson Services, Inc; Kolon TissueGene, Inc.; The Future of Biotechnology; Novartis AG; NuVasive®, Inc.; Pharmicell Co.,Ltd.; Stemedica Cell Technologies, Inc.; Takeda Pharmaceutical Company Limited.; and Tegoscience.
These companies are actively engaged in various strategies such as partnerships, mergers, reduction in production costs, launching new products, and implementing advanced technologies to boost their global presence. For instance,
- On January 10, 2022, Castel Creek Biosciences, a leading lentiviral-based cell and gene therapy company, acquires Novavita Thera Inc., a principal gene therapy company, to expand their innovative cell and gene therapy platforms worldwide. This acquisition will help Castel Creek Biosciences to develop its pipeline beyond the skin and connective tissue disorders to rare liver diseases by using new vivo capabilities with their existing approaches.
Request For Customization
Enquiry Before Buying
Speak With Analyst
